Lv31
396 积分 2024-07-18 加入
Triplet regimens for all: genomically agnostic approaches to improve on HMA + VEN in AML?
8小时前
已完结
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
1个月前
已完结
Thrombospondin-1–CD47 signaling contributes to the development of T cell exhaustion in cancer
1个月前
已完结
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
1个月前
已完结
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
1个月前
已完结
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial
1个月前
已完结
Brief Report: Ivonescimab Combined With Etoposide Plus Carboplatin as First-Line Treatment for Extensive-Stage SCLC: Results of a Phase 1b Clinical Trial
1个月前
已完结
Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
1个月前
已完结
Pathological complete response after neoadjuvant immunotherapy for a patient with microsatellite instability locally advanced rectal cancer: should we adapt our standard management for these patients?
1个月前
已完结
皖公网安备34019202002308
